Archive | September, 2020

LSN Launches Healthtech Partnering Week, Partners with Mary Furlong & Associates on New Longevity Partnering Event

24 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

The Inaugural Life Science Nation (LSN) Healthtech Partnering Week 2021 launches January 11-15, 2021 with three back-to-back digital partnering conferences: Redefining Early Stage Investments (RESI), 4D Meets AI, and Longevity, Health & Innovation (LHI). LSN’s RESI conference series has been very successful co-located with the J.P. Morgan Annual Healthcare Conference and will continue to grow with its two newest digital partnering conferences as a healthcare event trifecta.

LSN is proud to announce the newest digital partnering conference, Longevity, Health & Innovation, co-organized with Mary Furlong & Associates, the preeminent leader in the longevity education market. While Covid has ravaged the conference and event industry, LSN has seen tremendous growth in early-stage partnerships throughout life science and healthcare and looks forward to expanding through the week-long partnering event. The need to connect buyers and sellers is greater than ever, and LSN is proud to partner with Mary Furlong & Associates to facilitate these conversations in the longevity market.

Learn more about the three events:

Redefining Early-Stage Investments (RESI) – January 11-13, 2021

The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together startups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding.

4D Meets AI (4D) – January 14-15, 2021

Artificial intelligence (AI) is rapidly reshaping the healthcare landscape, and redefining what is possible in life science. The business of AI is broken down into two groups: the buyers and the sellers. 4D Meets AI is a partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health (the 4 Ds) to revolutionize healthcare. In addition to pitch sessions and one-on-one meetings hosted by our premier partnering platform, 4D Meets AI features investor and application panels to expand your knowledge of the industry and learn the latest trends and developments. This two-day digital conference provides the opportunity to meet strategic partners, learn from the experts, and build relationships to advance the future of healthcare.

Longevity, Health & Innovation (LHI), Co-Organized with Mary Furlong & Associates – January 14-15, 2021

The aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. Longevity, Health & Innovation (LHI) is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. LHI brings fundraising startups together with investors in longevity innovation to make deals in order that today’s seniors live longer, healthier lives.

Announcing Digital RESI November Panels

24 Sep

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claire

Life Science Nation (LSN) is pleased to announce its newest Digital RESI taking place November 17-19, 2020. Digital RESI is a powerful gathering focused on early-stage funding across all verticals of life science: drugs, devices, diagnostics, digital health. Attendees can meet with hundreds of investors and strategic partners from five continents over three days using RESI’s unique partnering platform, which identifies targets based on best fit for your technology and stage of development.

RESI is building on the success of Digital RESI September and keeping the conversations going beyond partnering with a new lineup of live panels. Check out the panels and descriptions and save $150 on registration with super early bird discount code: SUPEREBNOV.

EARLY STAGE THERAPEUTICS INVESTORS
Bringing the Newest Therapies to the Clinic
This panel aims to bring a diverse group of experts & senior decision making staff from VCs, corporate pharma, and other investor types together to discuss topics such as:
  • How they make decisions
  • What can startups do to be more attractive?
  • Areas of high need
  • Overcrowded areas
  • Common mistakes/red flags
The moderator will guide the discussion through topics including how the investors source & vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.
MEDICAL DEVICE INVESTORS
Investing in Novel Engineering
 This panel focuses on investment in new medical devices from development stage through to early commercialization. Topics may include:

  • What are investors looking for?
  • Areas of interest
  • Overcrowded areas
  • How to approach an investor
  • Successful deals they’ve done before
  • Common mistakes/Red flags

Panelists will discuss how to meet the challenges of raising financing for a new device and advise startups on how to make the investment case for their novel technology. Panelists will also explore what technology areas are of top interest to them and how a startup can get them into dialogue regarding an investment or deal.
DIAGNOSTICS INVESTORS
New Generation of Technologies Changing Treatment Paradigms
This panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:
  • Current areas of interest
  • Current challenges in this ecosystem – Navigating the competitive landscape
  • Commonly observed red flags
  • Successful deals
Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.
DIGITAL HEALTH
Leveraging Software to Lower Costs and Improve the Quality of Care
This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, change how care is delivered or managed, and how patients are involved in their own care. Panelists will explore topics related to investing in digital health, including:
  • In what kinds of digital health technologies are they interested in investing?
  • What metrics and evidence do you look for in a digital health startup?
  • How can an early stage digital health company demonstrate the value of their products?
  • What are the main challenges for startups raising capital in this space?
The moderator and panelists will discuss this rapidly evolving field of healthcare investment, and will introduce the audience to the key fundraising opportunities and challenges facing digital health entrepreneurs today.
CORPORATE VENTURE CAPITAL
The Corporate Landscape Morphed & New Opportunities Abound
This panel discusses what strategies are employed by corporate venture capital firms for investments and partnerships with early-stage companies. Potential topics for the panel include:
  • What corporate VCs look for in companies
  • What working with a corporate VC entails
  • What companies should do to be relevant to the corporate VC
Panelists could also discuss the relationship between the corporate venture capital firm and the parent company and how it affects investment criteria.
FAMILY OFFICES & ANGELS
How Do Family Offices View Seed & Series A Rounds?
When Life Science Nation (LSN) first launched the Redefining Early Stage Investments Conference Series (RESI), we focused on bringing investors from beyond venture capital to meet face to face with entrepreneurs. Angels and family offices are two of these alternative sources of early stage capital. These investor types are distinct from each other in many ways but also work well together. The Angels & Family Offices panel will introduce RESI’s entrepreneurs to these distinctions and also the ways in which these private capital pools are working together to fund healthcare innovation.
  • What do Angels and Family Offices have in common?
  • How do Angels and Family Offices plan their investment horizons?
  • Are Angels and Family Offices looking at the same sectors and opportunities as VCs?

Digital RESI Format Delivers Promising Results

24 Sep

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

Life Science Nation (LSN) was preparing for RESI Europe to take place on March 23, 2020 in Paris when the world turned upside-down. Like so many across the globe clamoring to pivot with the changing tides, LSN had to make an unprecedented decision to either cancel the conference or pivot to a digital format with only two weeks’ notice.

At the time, it remained unclear if the core value of the RESI conference series—making meaningful connections through partnering meetings and investor and workshop panels—would be feasible in a digitally delivered conference, but the benefits far outweighed the challenges. The result exceeded even the most optimistic projections as the team worked to transform a regional European event into a truly global event, with participants representing five continents, many of whom would not have traveled to Paris, regardless of the global pandemic. The transition to the digital format has broken down barriers and reduced travel costs in a meaningful way, making the Digital RESI events more accessible than ever. Since March, there have been five Digital RESI events yielding promising trends.

The transition to Digital RESI has enabled the enhancement of the partnering platform, creating many more meeting slots to facilitate meetings among participants from different countries and time zones, mirroring the cross-border industry trends this year. The chart below represents an increase in both the percentage of meetings accepted at the Digital RESI conferences as compared to the pre-pandemic on-site conferences, as well as in the average total number of meetings taking place at each conference.

This encouraging example of adaptation and resilience in the early-stage life science industry bodes well for the future of deal-making across drugs, devices, diagnostics, and digital health. LSN is proud to be a part of the process in a time where these deals have the potential to truly change the world.

Hot Investor Mandate: Singapore VC Firm Invests in Medical Devices, Synthetic Biology, and Digital Health Companies Interested in Asian Market

24 Sep

A venture capital firm based in Singapore with an additional office in the USA makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Cross-Border VC Firm with USD and RMB Funds Invest Up to $25M in All Life Science Sectors with Large Market Potential

24 Sep

A healthcare-focused venture capital firm manages 2 funds, a RMB denominated fund and a parallel USD fund. With the USD fund, the firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Fund Invests Up to $20M, With Interests in Platform Technologies, AI-Based Drug Discovery Companies, Etc.

24 Sep

A VC fund based in the USA that was founded in 2016 invests in many sectors, including cloud based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Chinese Private Investment Firm Seeks Unique, Disruptive Medical Devices for Home Use, IVD, Surgical Equipment, and More

24 Sep

A private investment firm based in Beijing, China and focused on medical device technologies is formed by pharmaceutical and medical device industry veterans and high-net-worth individuals with a committed capital of US$15 million. Typical investment size ranges from US$1-5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however it can aid in identifying strategic partners in the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries